Weiss Ratings Reaffirms "Sell (D)" Rating for Baxter International (NYSE:BAX)

Key Points

• Weiss Ratings has reiterated a "Sell (D)" rating for Baxter International, indicating continued pessimism regarding the stock's performance.
• Several research firms, including Goldman Sachs and Citigroup, have downgraded their ratings and adjusted target prices for Baxter International, with Citigroup lowering its price target from $34.00 to $32.00.
• Baxter reported earnings of $0.59 per share, which fell short of the consensus estimate of $0.60, reflecting a negative net margin and a slight revenue increase of 4.3% compared to the previous year.

Baxter International (NYSE:BAX - Get Free Report)'s stock had its "sell (d)" rating reiterated by Weiss Ratings in a report issued on Friday,Weiss Ratings reports.

BAX has been the topic of several other research reports. The Goldman Sachs Group lowered Baxter International from a "buy" rating to a "neutral" rating and set a $25.00 target price on the stock. in a research note on Friday, August 1st. Wall Street Zen lowered Baxter International from a "buy" rating to a "hold" rating in a research note on Saturday, August 2nd. Citigroup lowered their price target on Baxter International from $34.00 to $32.00 and set a "neutral" rating for the company in a report on Wednesday, July 9th. Morgan Stanley lowered their price target on Baxter International from $28.00 to $27.00 and set an "underweight" rating for the company in a report on Tuesday, July 15th. Finally, Evercore ISI lowered their price target on Baxter International from $33.00 to $31.00 and set an "outperform" rating for the company in a report on Tuesday, October 7th. Three analysts have rated the stock with a Buy rating, six have assigned a Hold rating and two have assigned a Sell rating to the company's stock. Based on data from MarketBeat, the company presently has an average rating of "Hold" and an average target price of $28.89.

Baxter International Trading Up 0.0%

NYSE:BAX traded up $0.00 during mid-day trading on Friday, hitting $22.99. The company had a trading volume of 3,719,462 shares, compared to its average volume of 5,464,974. Baxter International has a fifty-two week low of $21.33 and a fifty-two week high of $37.74. The business's fifty day moving average is $23.46 and its two-hundred day moving average is $27.17. The company has a debt-to-equity ratio of 1.30, a quick ratio of 1.49 and a current ratio of 2.30. The firm has a market cap of $11.81 billion, a P/E ratio of -76.65, a P/E/G ratio of 0.75 and a beta of 0.58.

Baxter International (NYSE:BAX - Get Free Report) last released its earnings results on Thursday, July 31st. The medical instruments supplier reported $0.59 earnings per share for the quarter, missing the consensus estimate of $0.60 by ($0.01). Baxter International had a negative net margin of 1.42% and a positive return on equity of 16.96%. The company had revenue of $2.81 billion during the quarter, compared to analyst estimates of $2.82 billion. During the same period in the previous year, the company posted $0.68 EPS. The company's quarterly revenue was up 4.3% compared to the same quarter last year. Baxter International has set its Q3 2025 guidance at 0.580-0.620 EPS. FY 2025 guidance at 2.420-2.520 EPS. As a group, research analysts expect that Baxter International will post 2.48 earnings per share for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the company. Dodge & Cox grew its holdings in shares of Baxter International by 1.3% during the second quarter. Dodge & Cox now owns 52,121,620 shares of the medical instruments supplier's stock worth $1,578,243,000 after buying an additional 662,695 shares in the last quarter. Geode Capital Management LLC grew its holdings in shares of Baxter International by 2.6% during the second quarter. Geode Capital Management LLC now owns 12,882,960 shares of the medical instruments supplier's stock worth $388,416,000 after buying an additional 326,652 shares in the last quarter. Ameriprise Financial Inc. grew its holdings in shares of Baxter International by 1.3% during the second quarter. Ameriprise Financial Inc. now owns 7,638,629 shares of the medical instruments supplier's stock worth $231,304,000 after buying an additional 97,687 shares in the last quarter. Sound Shore Management Inc. CT grew its holdings in shares of Baxter International by 13.7% during the first quarter. Sound Shore Management Inc. CT now owns 2,825,902 shares of the medical instruments supplier's stock worth $96,731,000 after buying an additional 341,321 shares in the last quarter. Finally, Russell Investments Group Ltd. grew its holdings in shares of Baxter International by 13.4% during the second quarter. Russell Investments Group Ltd. now owns 1,900,828 shares of the medical instruments supplier's stock worth $57,568,000 after buying an additional 224,804 shares in the last quarter. 90.19% of the stock is currently owned by institutional investors.

Baxter International Company Profile

Baxter International Inc, through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company operates through four segments: Medical Products and Therapies, Healthcare Systems and Technologies, Pharmaceuticals, and Kidney Care. The company offers sterile intravenous (IV) solutions; infusion systems and devices; parenteral nutrition therapies; generic injectable pharmaceuticals; surgical hemostat and sealant products, advanced surgical equipment; smart bed systems; patient monitoring and diagnostic technologies; and respiratory health devices, as well as advanced equipment for the surgical space, including surgical video technologies, precision positioning devices, and other accessories.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.